Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05048368 | Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function | withdrawn | Phase 1 | 0 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03804255 | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting | withdrawn | — | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06895681 | UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations | withdrawn | — | 0 | University of California, San FranciscoOTHER | 0 | Sep 2, 2026 | clinicaltrials |
| NCT04605614 | 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07449481 | A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors | withdrawn | Phase 2 | 0 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Ankyra Therapeutics, IncINDUSTRY | 0 | Jun 25, 2026 | clinicaltrials |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 2 | Jun 10, 2026 | clinicaltrials |
| NCT07534813 | A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors | withdrawn | N/A | 0 | Grit BiotechnologyINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07152236 | Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors | withdrawn | N/A | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT06145802 | Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors) | withdrawn | N/A | 0 | Grit BiotechnologyINDUSTRY | 0 | Apr 29, 2026 | clinicaltrials |
| NCT05660421 | Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors | withdrawn | Phase 2 | 0 | Douglas JohnsonOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT05982522 | IN10018 Combination Therapy in Previously-treated Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 24, 2025 | clinicaltrials |
| NCT04372641 | Testing the Safety of CB-5339 in Patients With Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04557709 | Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT06235541 | A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Genome & CompanyINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06416436 | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | withdrawn | Phase 1 | 0 | University of Kansas Medical CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06719973 | Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) | withdrawn | Phase 1 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Jun 17, 2025 | clinicaltrials |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | withdrawn | — | 0 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04820894 | Perception of Cure Among Patients With Metastatic Cancer | withdrawn | — | 0 | City of Hope Medical CenterOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT05600556 | Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT) | withdrawn | N/A | 0 | Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06834386 | Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients | withdrawn | Phase 4 | 0 | Mayo ClinicOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05828303 | A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Turning Point Therapeutics, Inc.INDUSTRY | 6 | Apr 1, 2025 | clinicaltrials |
| NCT06365918 | Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05653661 | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06331598 | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)(IMperator) | withdrawn | Phase 2 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05231733 | Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors | withdrawn | Phase 1 | 0 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 0 | Oct 31, 2024 | clinicaltrials |
| NCT06161493 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | withdrawn | Phase 1 | 0 | Haider MahdiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06372574 | A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors | withdrawn | Phase 1 | 0 | Genentech, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT05515692 | Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Jul 23, 2024 | clinicaltrials |
| NCT05039931 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05403580 | Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | withdrawn | Phase 3 | 0 | Mayo ClinicOTHER | 0 | May 6, 2024 | clinicaltrials |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 6, 2024 | clinicaltrials |
| NCT05678283 | A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06284226 | An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients(CCT-ANK-11) | withdrawn | Early Phase 1 | 0 | Beijing Kejing Biotechnology Co., Ltd.INDUSTRY | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06219499 | Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841 | withdrawn | Phase 1 | 0 | OncoC4, Inc.INDUSTRY | 0 | Apr 3, 2024 | clinicaltrials |
| NCT04294875 | Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies(MPT0B64) | withdrawn | Early Phase 1 | 0 | J Ints BioINDUSTRY | 0 | Mar 6, 2024 | clinicaltrials |
| NCT03905538 | Evaluation of [18F]FLT PET/CT as an Early Predictor of Outcome in Pediatric Solid Tumors | withdrawn | Early Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT05099536 | 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | 3D Medicines (Beijing) Co., Ltd.INDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT05791474 | ATI-2231 in Advanced Solid Tumor Malignancies | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials